Table 4: One and two-year relative survival (with 95% confidence intervals) according to age, sex, smoking habit, lung disease, performance status, morphology, stage, surgery, radiotherapy, chemotherapy, and targeted treatment for lung cancer patients diagnosed in 2011–2012.
|
|
One-year RS (95% CI) |
Two-year RS (95% CI) |
|
Age |
||
|
15-44 |
37.5 (20.9-67.5) |
25.0 (11.5-54.5) |
|
45-54 |
42.4 (32.8-54.8) |
23.2 (14.9-36.3) |
|
55-64 |
43.5 (36.2-52.4) |
24.2 (17.4-33.6) |
|
65-74 |
36.6 (30.4-44.0) |
19.1 (14.0-25.9) |
|
≥75 |
22.4 (17.5-28.6) |
11.2 (7.5-16.6) |
|
Sex |
||
|
Men |
31 (27.4-35.2) |
15.8 (12.8-19.7) |
|
Women |
47.6 (39.1-57.9) |
28.9 (21.2-39.4) |
|
Smoker |
||
|
No |
53.1 (43-65.6) |
32.7 (23.2-46.1) |
|
Yes |
32.0 (28.1-36.4) |
16.8 (13.6-20.8) |
|
Lungdisease |
||
|
No |
38.1 (33.6-43.1) |
20.9 (17-25.6) |
|
Yes |
28 (22.8-34.4) |
14.0 (9.9-19.8) |
|
Performance status |
||
|
ECOG<2 |
43.5 (38.9-48.7) |
23 (18.8-28.1) |
|
ECOG ≥ 2 |
11.5 (7.2-18.3) |
1.8 (0.6-5.9) |
|
Morphology |
||
|
NSmCC |
43.4 (38.9-48.5) |
23.4 (19.3-28.4) |
|
SmCC |
27.8 (20.3-38.0) |
12.4 (7.1-21.5) |
|
Non-microscopic verification |
7.6 (4.1-14.0) |
4.1 (1.7-9.9) |
|
Stage |
||
|
I |
89.7 (82.1 – 97.9) |
66.5 (54.3 – 81.5) |
|
II |
62.0 (47.4 – 81.1) |
44.1 (29.4 – 66.1) |
|
III |
41.4 (34.6 – 49.6) |
21.1 (15.3 – 29.2) |
|
IV |
16.8 (13.4 – 21.0) |
5.4 (3.5 – 8.4) |
|
Surgery |
||
|
Done |
89.2 (82.9 – 96.0) |
69.0 (59.1 – 80.6) |
|
Not done |
23.8 (20.5 – 27.6) |
9.2 (6.9 – 12.2) |
|
Radiotherapy |
||
|
Done |
46.4 (39.7 – 54.3) |
23.1 (17.2 – 31.0) |
|
Not done |
29.0 (25.2 – 33.4) |
16.0 (12.8 – 20.1) |
|
Chemotherapy |
||
|
Done |
43.1 (37.8 – 49.1) |
20.1 (15.7 – 25.9) |
|
Not done |
26.2 (21.9 – 31.2) |
16.1 (12.4 – 20.9) |
|
Targeted treatment |
||
|
Done |
67.8 (52.8 – 87.0) |
27.7 (15.3 – 50.1) |
|
Not done |
31.9 (28.4 – 35.9) |
17.8 (14.7 – 21.4) |
RS relative survival, CI confidence intervals, NSmCC non-small cell carcinoma, SmCC small cell carcinoma